Covered Business Method Reviews cut litigation costs from $200–$300 k to roughly $25 k and limit the decision to 18 months. Eligibility requires a claimed method that directly supports a financial product or service, excluding tech‑specific inventions. Filing starts at $12 k for up to 20 claims with cost per additional claim and a 12‑month final review. The 2020 sunset forces you to prove market impact via studies. Use CBM for protection, and you’ll uncover how to safeguard your portfolio.
Key Takeaways
- CBM reviews eliminate many discovery costs, granting protection for claims supporting a financial product or service filed after 9/16/2012.
- Petitioner must prove the claim directly supports the financial product/service; tech‑specific claims are excluded under PTAB’s two‑step test.
- Filing costs: $12k for ≤20 claims (plus $25k for the PGR‑equivalent tier), with a mandatory $38k minimum total and an 18‑month adjudication timeline.
- Ground basis: novelty, non‑obviousness, description, enablement, indefiniteness; sunset in 2020 removed automatic defensibility, demanding valuation evidence for each claim.
- Post‑sunset, lenders require independent market valuations; patch portfolios by diversifying into cross‑technology sectors while pursuing IPR or PGR for remaining claims.
Why Covered Business Method Reviews Matter
Because the Covered Business Method (CBM) review delivers substantial savings, it’s a critical tool for any company facing a patent assertion. You can cut filing fees to $16,000–$22,000, far below the $200–$300k costs of full federal litigation, and you avoid expensive discovery. By convening an administrative trial, you reduce attorney time, and you share costs with other defendants targeting the same patent. CBM’s broader invalidity grounds—lack of novelty, non‑obviousness, insufficient description, enablement, indefiniteness—give you a stronger Innovation Defense than traditional IPR or PGR routes. The program’s short nine‑month eligibility window keeps you in the action before lines of defense blur. Stopping low‑quality business‑method patents from staying enforceable builds Corporate Resilience, and it shields mid‑size firms from predictable predatory suits. You also benefit from a swift resolution, often within six months, which preserves cash flow and operational focus. Overall, CBM’s structure turns costly litigation into a strategic, cost‑effective shield.
Unlike traditional litigation, the CBM review operates under the principle of no presumed validity, ensuring a more balanced dispute.
How to Determine CBM Eligibility
To determine CBM eligibility, you first verify that the patent’s claims describe a method that directly supports a financial product or service—such as banking, insurance, or securities handling—while excluding any technological invention. Next, perform claim mapping to confirm each claim element belongs to a financial process, not a technical improvement. Check the patent’s filing date; only those with effective dates on or after September 16, 2012 qualify pre‑AIA. Verify petitioner standing by providing evidence that the patent is used within a financial product or service. PTAB will then apply a two‑step test: (1) claims are tied to a financial product or service; (2) they do not fall under tech exclusion. Analyze the specification and prosecution history for any tech‑specific solutions or data‑handling steps that could trigger exclusion. If the claims pass both steps, the patent is eligible for CBM review, subject to the statutory 35 U.S.C. § 324(e) limitation and it remains enforceable forward. To qualify for ACBM, a board member must accumulate at least 30 training points within a single calendar year.
What Are the Costs and Timelines for a CBM?
When you file a CBM request, the fee schedule starts at $12,000 for up to 20 claims—up to $25,000 if you opt for the PGR equivalent tier—and climbs by $250 to $595 for each claim over that limit. CBM petitions are only available for eligible patents that cover financial products or services without a technological invention. Your fee breakdown follows: $12,000 (or $16,000) for the initial request, plus $250 per excess claim; PGR‑equivalent levels cost $25,000 for 20 claims, with $595 extra per claim. Post‑institution fees top out at $34,375 for 20 claims; any surplus claim adds $550, and a minimum official total of $38,000 is required. Attorney costs sit on top of these government fees. The process duration reaches a maximum of six months from filing to an institution decision, then twelve months to a final written ruling—totaling roughly eighteen months. A single six‑month extension is possible if you show good cause, but most cases finish within a year and you can track progress online.
How the 2020 Sunset Will Affect Your Portfolio
If you previously relied on CBM to shore up your portfolio’s durability, the 2020 sunset has erased that safeguard, compelling you to substantiate patent value through third‑party market data and independent expert appraisals. Without CBM, value drift accelerates as your patents no longer command automatic defensibility. You must consequently map each claim to demonstrable market impact, using independent valuation studies and real‑world licensing data. A diversification gap creeps in when concentrated holdings lack cross‑technology buffers, exposing you to obsolescence and competitive erosion. To counter this, layer your portfolio across emergent sectors, ensuring that a single failure doesn’t collapse collateral strength. Lenders reassess collateral on quality metrics, requiring high‑fidelity valuations. In financing deals, balanced technical breadth improves the loan‑to‑value ratio and reduces covenant pressure substantially. Finally, maintain rigorous upkeep, prioritize renewal and enforcement costs, and prune obsolete patents to keep the portfolio lean and compliant with evolving market demands.
Remember that a patent provides a 20‑year exclusive right to exclude competitors.
What Next If CBM Is No Longer Available?
Since CBM expires, you must pivot to a new post‑granted enforcement strategy. IPR Alternatives remain your primary tool; IPR challenges novelty and obviousness under 35 U.S.C. §§ 102, 103, but exclude § 101 and § 112 grounds available in CBM. Most of our AIA applications ran through IPR, and without CBM, those regimes now dominate. PGR Usage, conversely, is constrained to a nine‑month window post‑issuance and permits broader grounds, including § 101 and § 112, yet it lacks standing for older patents and is rarely exploited. Litigation has surged—trips of suits against financial firms since CBM’s end—increasing discovery costs and demanding district‑court defense tactics such as § 101 summary judgments or venue motions, mirroring CBM success rates. Consequently, prepare for costlier discovery, robust PTAB‑style briefing, and strategic filing within the narrow PGR period. Focus on swift procedural action, leverage prior PTAB decisions, and budget for extended discovery to maintain competitive posture and win. With the CBM program officially CBM program terminated, defendants must pivot away from PTAB challenges and concentrate on alternative strategies.
Frequently Asked Questions
Can CBM Challenge Patents Granted to Non‑Financial Businesses?
Yes, you can challenge patents granted to non‑financial businesses, provided those claims fall under the Business Scope of CBM. The court treats any method that manages financial products or services—regardless of the industry—as Patent Eligible for CBM scrutiny. Even if the patent’s text avoids financial terms, its specification must reveal a financial context; then you may file an action on all 101‑112 grounds to strengthen your position by claiming validity.
What Is the Appeal Process After a CBM Denial?
Swift steps set the stage: you won’t miss filing a Notice of Appeal within 63 days of the PTAB denial, serve parties in two days, await CAFC docketing. Appeal timelines start with a 14‑day docketing window, then 40 days for brief, 30 for appellee, 21 for reply. Re‑examination rules apply only if the court remands, allowing new evidence under limited circumstances. Oral argument lasts 15 minutes, concluding on the record.
How Do CBM Outcomes Affect Downstream Licensing Agreements?
CBM outcomes directly reshape downstream licensing agreements: invalidated claims erode the value of existing patents, forcing licensors to renegotiate royalty structures and incorporate contractual flexibility clauses. You’ll find that licensed parties must adopt tiered or milestone‑based payments to align with diminished patent strengths, while add‑on flexibility provisions allow rapid adjustment as new CBM decisions surface. This dynamic guarantees that contractual terms remain enforceable despite shifting patent landscapes in the next.
Are There Alternative Programs to Address Low‑Quality Business Method Patents?
You’ll address today’s low‑quality business method patents through several programs. Post‑Grant Review and Inter‑Parties Review offer broad validity challenges, while Ex‑Parte Reexamination provides a low‑threshold, examiner‑led route. Policy reform can streamline Patent Triage by prioritizing weak claims at filing. These mechanisms together curtail costly litigation and promote efficient patent quality enforcement. Additionally, district court litigation remains an option for §101 challenges, though it tends to be resource‑intensive, and decisive resolution.
What Evidence Is Required to Prove a Claim Is “Financial Activity”?
Proof thresholds rely on demonstrable financial relevance. You must show, using data indicators, that the claim covers a payment, credit, or other banking activity. Cite patent titles, assignment records, and text frequency of terms like “financial transaction” or “payment system.” Statistical analysis of your dataset should reveal >30% financial terms, and third‑party audits confirm the practice aligns with regulated finance. This satisfies preponderance in PTAB reviews and convincingly presented analysis.
Conclusion
Standing at the edge of the CBM horizon, you recognize its necessity like weather‑proofing a critical structure. Once you qualify, you’ll file, file, and file, closing the 6‑month window before the 2020 sunset dims the shield. Cost‑tailored analysis guarantees you avoid the 200‑Million‑Euro blind spot. Should the review fade, pivot instantly: align with the USPTO’s Post‑Sunset pathway or transfer rights. Your patents remain resilient, a fortress weathered by engineering to keep your portfolio safe today.
Lawyer
